| Literature DB >> 35399824 |
Rupesh V Chikhale1, Saurabh K Sinha2, Pukar Khanal3, Nilambari S Gurav4, Muniappan Ayyanar5, Satyendra K Prasad6, Manish M Wanjari7, Rajesh B Patil8, Shailendra S Gurav9.
Abstract
Background: Since December 2019, SARS-CoV-2 had been a significant threat globally, which has accounted for about two million deaths. Several types of research are undergoing and have reported the significant role of repurposing existing drugs and natural lead in the treatment of COVID-19. The plant Phyllanthus emblica (Synonym-Emblica officinalis) (Euphorbiaceae) is a rich source of vitamin C, and its use as an antiviral agent has been well established. Purpose: The present study was undertaken to investigate the potency of the several components of Phyllanthus emblica against three protein targets of 2019-nCoV viz. NSP15 endoribonuclease, main protease, and receptor binding domain of prefusion spike protein using molecular docking and dynamics studies.Entities:
Keywords: Amlaki; Ayurveda; COVID19; Chlorogenic acid; Emblica officinalis; Molecular Dynamics; Myricetin; Pandemic
Year: 2021 PMID: 35399824 PMCID: PMC8276571 DOI: 10.1016/j.phyplu.2021.100095
Source DB: PubMed Journal: Phytomed Plus ISSN: 2667-0313
Fig. 1GO analysis (a) Cellular components, (b) Molecular function and (c) Biological process.
Fig. 2Interaction of phytoconstituents with their targets and regulated pathways.
Fig. 31(a) RMSD of NSP15 endoribonuclease; 1(b) RMSF of NSP15 endoribonuclease; 1(c) RMSD of Chlorogenic acid; 1(d) Initial binding pose of Chlorogenic acid with NSP15 endoribonuclease and; 1(e) Binding pose of Chlorogenic acid with NSP15 endoribonuclease towards the end of the simulation. 2(a) RMSD of NSP15 endoribonuclease; 2(b) RMSF of NSP15 endoribonuclease; 2(c) RMSD of Remdesivir; 2(d) Initial binding pose of Remdesivir with NSP15 endoribonuclease and; 2(e) Binding pose of Remdesivir with NSP15 endoribonuclease towards the end of the simulation.
Fig. 41(a) RMSD of SARS-CoV-2 main protease; 1(b) RMSF of SARS-CoV-2 main protease; 1(c) RMSD of Quercitrin; 1(d) Initial binding pose of Quercitrin with SARS-CoV-2 main protease and; 1(e) Binding pose of Quercitrin with SARS-CoV-2 main protease towards the end of the simulation. 2(a) RMSD of SARS-CoV-2 main protease; 2(b) RMSF of SARS-CoV-2 main protease; 2(c) RMSD of Remdesivir; 2(d) Initial binding pose of Remdesivir with SARS-CoV-2 main protease and; 2(e) Binding pose of Remdesivir with SARS-CoV-2 main protease towards the end of the simulation.
Fig. 51(a) RMSD of SARS-CoV-2 RBD; 1(b) RMSF of SARS-CoV-2 RBD; 1(c) RMSD of Myricetin; 1(d) Initial binding pose of Myricetin with SARS-CoV-2 RBD and; 1(e) Binding pose of Myricetin with SARS-CoV-2 RBD towards the end of the simulation. 2(a) RMSD of SARS-CoV-2 RBD; 2(b) RMSF of SARS-CoV-2 RBD; 2(c) RMSD of Remdesivir; 2(d) Initial binding pose of Remdesivir with SARS-CoV-2 RBD and; 2(e) Binding pose of Remdesivir with SARS-CoV-2 RBD towards the end of the simulation.
MMGBSA results for binding energies of selected complexes.
| Compounds-Protein | Glide Score Kcal/mol | MM-GBSA* | ||||||
|---|---|---|---|---|---|---|---|---|
| ΔEVDW | ΔEELE | ΔGGB | ΔGSurf | ΔGgas | ΔGSol | ΔGbind | ||
| Chlorogenic acid (PDB: | -8.397 | -17.91 (3.72) | -113.92 (26.11) | 128.98 (20.69) | -2.90 (0.47) | -126.50 (24.28) | 126.08 (20.55) | -0.42 (4.98) |
| Remdisvir (PDB: | -5.94 | -36.63 (4.56) | -21.07 (6.89) | 39.26 (5.96) | -4.99 (0.61) | -47.52 (8.60) | 34.26 (5.77) | -13.31 (5.05) |
| Quercitrin-(PDB: | -9.043 | -35.24 (4.20) | -33.14 (16.06) | 46.81 (10.81) | -5.20 (0.23) | -77.88 (15.64) | 41.60 (10.57) | -36.27 (5.73) |
| Remdesivir-(PDB: | -7.766 | -46.83 (3.82) | -44.35 (7.82) | 58.47 (5.18) | -5.99 (0.30) | -80.07 (7.29) | 52.47 (5.08) | -27.59 (4.32) |
| Myricetin-(PDB: | -6.782 | -24.28 (2.46) | -21.62 (7.12) | 32.66 (6.10) | -3.89 (0.26) | -46.18 (7.09) | 28.77 (6.01) | -17.41 (2.62) |
| Remdesivir-(PDB: | -4.685 | -22.49 (4.33) | -23.38 (11.05) | 40.82 (9.18) | -3.59 (0.53) | -38.14 (12.29) | 37.23 (4.80) | -0.91 (4.80) |